
- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact



ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.

-
Notes & Comments
Haulica I, Bild W, Boisteanu D
New challenges and perspectives in physiology. From the classical concept of homeostasis to physiomeActa Endo (Buc) 2005 1(2): 233-239 doi: 10.4183/aeb.2005.233
References1. Cannon WB. The Wisdom of the Body, Norton Comp. Inc. New York, 1932.2. Lauralee Sherwood. Human physiology. Fourth edition. Brooks/Cole, Thomson Learning, Australia, Canada, U.S.A., 2001.3. Selye H. Annual Report on Stress. Acta Inc, Medical Publ, 1951.4. Watson JD, Crick FHC. Molecular structure of nucleic acids structure, 1953: 171, 737.5. Levin B. Genes. vol. V. Oxford University Press, 1994: 1091-1100.6. James P. Proteome Research: Mass Spectrometry, Springer, 2001.7. Barr M. Super models. Physiol Genomics 2003; 13:15-24.8. Ottoson D, Bartzai T, Hokfelt T, Fuxe K. Challenges and perspectives in neuroscience. Pergamon, U.S.A., U.K., Japan, 1995.9. Losel RM, Falkenstein E, Feuring M., Schultz A., Tillmann HC, Rossol-Haseroth K, Wehling M. Nongenomic Steroid Action: Controversies, Questions, and Answers Physiol Rev 2003; 83:965-1016.10. Wentherall JD. Gene therapy in perspective. Nature 1991; 349: 275-276. [CrossRef]11. Phillips M J and Gyurco R. Antisense oligonucleotides. New tools for physiology. News in Physiol. Sci 1997; 12: 99-105.12. Kamp RM, Kyriakidis D, Choli-Papadopoulu A. Proteome and protein analysis, Springer, 2000: 372.13. Wilkins MR, Williams KL, Appel RD. Proteome Research. New frontiers in Functional Genomics, Springer, 1997:243.14. Winslow RL, Boguski MS. Genome Informatics: Current Status and Future Prospects. Circulation Research 2003; 92:953-961. [CrossRef]15. Bassingthwaithe JB. A view of physiome. Conference Reports, Internat Congress Physiol Sci, St.Petersburg, 1997, LO63,11.16. Dzau V. Physiological genomics . The Physiologist 1997; 40(5): 205-209.17. Noble D. The Physiome Project in Understanding the Heart: the Cardiome. In: The Physiome Project, London, 1998.18. Haulica I, Rusu V, Bild W. Role of molecular biology in the progress of medical sciences. Rom. J. Physiol 1998; 35:1-2, 3-12.19. Haulica I. From molecular genetics to functional genomics in physiome. J. Cell. Mol. Med 2002; 6(4): 648- 653. [CrossRef]20. Swynghedauw B, Mausier P. Physiologie, Une science qui se reveille. Medecine/ Sciences 1999; 15: 868-872. -
Editorial
Ionescu-Tirgoviste C
Proinsulin as the possible key in the pathogenesis of type 1 diabetesActa Endo (Buc) 2009 5(2): 233-249 doi: 10.4183/aeb.2009.233
AbstractBased on epidemiological, clinic, biochemical and hormonal data (both personal and\r\ninternational), our personal view is that natural history of autoimmune type 1 diabetes could\r\ninclude the following stages: 1) The presence of a complex genetic predisposition towards ?\r\ncell autoimmunity (possibly “latent” until death); 2) The “initiation” of autoimmunity in\r\nsubjects carrying a defect in the post-translational processing of pre-proinsulin/ proinsulin/\r\ninsulin, manifested precociously as increased proinsulin-to-insulin ratio; 3) Stimulation by the\r\nincreased proinsulin of the plasmacytoid dendritic cell clones capable to capture the natural\r\nantigens (proinsulin/insulin, Glutamic Acid Decarboxylase, etc.) from the pancreatic beta\r\ncells; 4) Activation of the process generating reactive T cell clones (Teffs) in the detriment of\r\nprotective immuno-regulatory T cell clones (Tregs), triggering the anti-beta cell attack,\r\nexpressed as autoimmune insulitis and/or the presence of circulating anti beta cell antibodies;\r\n5) The onset of the beta cell apoptosis process mediated by pro-inflammatory cytokines (IFN\r\n?, TNF ?, IL6) or by the direct contact between Teffs and the beta cells; 6) Identification of\r\nthe first secretory beta cell defects (the loss of the first phase insulin response followed by the\r\nprogressive decrease of the area under the insulin curve and the progressive increase of the\r\narea under the blood glucose curve) while fasting glycemia is still normal; 7) The progressive\r\nloss of the beta cell mass. All these processes take place during the pre-hyperglycemic stage\r\nof diabetes, with a higher or lower speed depending on the genetic background. The overt\r\nclinical stage of diabetes, marked by the presence of hyperglycemia, occurs rather late, when\r\nmore than 90% of the beta cell function/mass is irreversibly lost. -
Book Review
Gheorghiu ML
Disorders of Statural and Weight GrowthActa Endo (Buc) 2008 4(2): 234-234 doi: 10.4183/aeb.2008.234
-
Notes & Comments
Caruntu C, Mirica A, Rosca AE, Mirica R, Caruntu A, Tampa M, Matei C, Constantin C, Neagu M, Badarau AI, Badiu C, Moraru L
The Role of Estrogens and Estrogen Receptors in Melanoma Development and ProgressionActa Endo (Buc) 2016 12(2): 234-241 doi: 10.4183/aeb.2016.234
AbstractMelanoma has a significant mortality and its growing incidence is associated with important social and health care costs. Thus, investigation of the complex mechanisms contributing to emergence and development of melanoma are of real interest both in scientific research and clinical practice. Estrogens play an important role in the emergence and development of certain types of cancer, such as breast cancer, endometrial cancer and ovarian cancer, but their role in development of cutaneous melanoma is still a matter of debate. Various data suggest that increased levels of endogenous estrogens during pregnancy or exposure to exogenous estrogens by use of oral contraceptives (OCs) and hormone replacement therapy (HRT) may have a potential role in melanoma development and progression. Moreover, there were revealed several intracellular pathways which can support the connection between estrogens, estrogen receptors (ER) and melanoma. While ER-β plays an antiproliferative role, ER-α promotes cell growth and cellular atypia. Thus, inhibition of ER-β activity in the skin can increase the risk for development of cutaneous melanoma and spread of metastatic cells. However, despite recent advances in this area, the exact role and clinical implications of estrogens and estrogen receptors in melanoma are still not entirely understood and require further investigations -
Editorial
Findeklee S, Kasoha M, Radosa JC, Radosa MP, Haj Hamoud B, Sima RM
Women and Men with Cancer and a Future Desire for Children - What Should Clinicians Consider in Covid-19 Pandemic Times?Acta Endo (Buc) 2021 17(2): 234-240 doi: 10.4183/aeb.2021.234
AbstractThe topic of fertility preservation has been gaining increasing importance since the beginning of this century. The reasons for this development are the advances in oncological therapy over the past few decades, with cure rates of approximately over 90%, and the fact that starting families is increasingly postponed in later periods of life in industrialized countries. Since March 2020 the whole medical and non-medical world experiences a pandemic due to Covid-19 (coronavirus disease 2019) which has never been seen before. This created a plenty of challenges for both, the patients and healthcare providers. This review article presents the fertility-protective methods currently available for women and men suffering from cancer with their clinical approach, value, advantages and disadvantages. Besides, it focuses on the changes and special considerations which have to be taken into account during pandemic times including preventive measures as well as the patient`s access to the fertility preserving options. In conclusion every premenopausal woman and every man with incomplete family planning suffering from cancer should be counselled about the existing fertility preserving techniques before commencing cancer therapy. -
Clinical review/Extensive clinical experience
Micic D, Polovina S, Micic Du, Macut D
Obesity and Gut-Brain AxisActa Endo (Buc) 2023 19(2): 234-240 doi: 10.4183/aeb.2023.234
AbstractEpidemic of obesity is ongoing and did not slow down. Causes of obesity are numerous and very complex. Among them, the concept of bidirectional signaling within the brain-gut-microbiome axis was recently proposed as possible pathophysiological mechanism and become a hot topic in the explanations for the control of food intake. Discoveries of new anti-obesity drugs that are analogs for the receptors for some hormones derived from gastrointestinal tract contribute to the investigations in this area. The human gut microbiota plays a fundamental role in human health and disease and it is considered that it represent an endocrine organ that participate in energy homeostasis and host immunity. Role of gut microbiome has been investigated in metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease. Gut microbiome participate in regulation of various mechanisms inside the gastrointestinal tract due to its production of different bacterial metabolites. In our manuscript we present current knowledge about microbiota in the gut; the relation between gut microbiota and brain; neuroendocrine system and gut-brain axis; immune system and gut-brain axis; endocrine system and gut-brain axis; the role of gut microbiota in obesity development and possible use of gut microbiota for the treatment of obesity. -
Editorial
Grigorie D, Sucaliuc A
Prevention of Falls and Fractures - To „D” or Not to „D”?Acta Endo (Buc) 2018 14(2): 235-237 doi: 10.4183/aeb.2018.235
Abstract- -
Book Review
Capatana C
Mathematical Modeling of Biological Systems Volume 1Acta Endo (Buc) 2008 4(2): 235-235 doi: 10.4183/aeb.2008.235
-
Book Review
Capatana C
Mathematical Modeling of Biological Systems Volume 2Acta Endo (Buc) 2008 4(2): 236-236 doi: 10.4183/aeb.2008.236
-
Case Report
Lungulescu C, Croitoru VM, Lungulescu C, Croitoru A, Paul D
Durable Response in a Case of Metastatic Anaplastic Thyroid Cancer Using a Combination of Tyrosine Kinase Inhibitors and a Check Point InhibitorActa Endo (Buc) 2020 16(2): 236-241 doi: 10.4183/aeb.2020.236
AbstractAnaplastic thyroid cancer (ATC) is a highly uncommon (less than 2% of thyroid malignancies) and aggressive type of cancer, with aggressive behavior and, therefore, exhibiting poor prognosis. ATC tumors are automatically labeled as stage IV disease regardless of standard criteria such as tumor burden or metastasis. ATC tumors require a diversified treatment approach that includes surgical resection, followed by a complete an aggressive combination of radiation and chemotherapy and/or palliative care. Despite best efforts, 1-year overall survival of patients is 20% to 40% with nearly universal mortality rate. Consequently, novel approaches (targeted therapy, immunotherapy) have been studied, alone or in combination, to improve the dire prognosis of these patients. BRAF V600E mutation is the most common genetic mutation found in ATC. We report the case of a 57-year-old man diagnosed with stage IVc (undifferentiated) ATC with hepatic and osseous metastases. The molecular analysis of the tumor revealed a V600E BRAF-mutation. The patient was treated with Dabrafenib and Trametinib, and achieved remission 5 weeks after starting the treatment. Subsequently, he had a thyroidectomy, and pembrolizumab was added to the two tyrosine kinase inhibitors. 9 months later he is still in remission. This case illustrates the importance of obtaining molecular information in anaplastic thyroid cancer and the urgent need of studies investigating the combination of tyrosine kinase inhibitors and check-point inhibitors in patients with V600E BRAF- mutations.